2024
DOI: 10.1002/wnan.1952
|View full text |Cite
|
Sign up to set email alerts
|

New insights into nanomedicines for oral delivery of glucagon‐like peptide‐1 analogs

Soraia Filipa Tavares Pinto,
Hélder Almeida Santos,
Bruno Filipe Carmelino Cardoso Sarmento

Abstract: Type 2 diabetes mellitus (T2DM) is a metabolic disorder that arises when the body cannot respond fully to insulin, leading to impaired glucose tolerance. Currently, the treatment embraces non‐pharmacological actions (e.g., diet and exercise) co‐associated with the administration of antidiabetic drugs. Metformin is the first‐line treatment for T2DM; nevertheless, alternative therapeutic strategies involving glucagon‐like peptide‐1 (GLP‐1) analogs have been explored for managing the disease. GLP‐1 analogs trigge… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 97 publications
0
0
0
Order By: Relevance